Clinical Proteomics Reveals Vulnerabilities in Noninvasive Breast Ductal Carcinoma and Drives Personalized Treatment Strategies
This study provides real-world evidence for DCIS, a disease for which currently no molecular tools or biomarkers exist, and gives an unbiased, comprehensive, and deep proteomic profile, identifying >380 actionable targets.
Authors
- Adriana Aguilar‐Mahecha (ORCID: https://orcid.org/0000-0002-1015-4383)
- Gerald Batist (ORCID: https://orcid.org/0000-0001-5430-3750)
- René P. Zahedi (ORCID: https://orcid.org/0000-0002-4960-5460)
- Livia Florianova (ORCID: https://orcid.org/0009-0002-0616-9379)
- Georgia Mitsa (ORCID: https://orcid.org/0009-0002-8453-6664)
- Mark Basik (ORCID: https://orcid.org/0000-0002-2633-5410)
- Christoph H. Borchers (ORCID: https://orcid.org/0000-0003-2394-6512)
- Sonia Victoria Del Rincon (ORCID: https://orcid.org/0000-0002-6350-0227)
- Josiane Lafleur
Institutions
- Jewish General Hospital (CA)
- CancerCare Manitoba (CA)
- IGNIS Innovation (Canada) (CA)
- Research Institute in Oncology and Hematology (CA)
- University of Manitoba (CA)
- McGill University (CA)
- The University of Winnipeg (CA)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2024-12-26
- DOI
- https://doi.org/10.1158/2767-9764.crc-24-0287
- Primary Topic
- Advanced Proteomics Techniques and Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- McGill University
- Faculty of Medicine, McGill University
- Genome Canada
- Fondation du cancer du sein du Québec
- Jewish General Hospital
- Fondation De Famille Alvin Segal
- Warren Y. Soper Charitable Trust
- National Cancer Institute